Halozyme Q3 net income rises 41% to $247.05 million
Bitget2026/11/05 21:30- Halozyme Therapeutics’ third-quarter 2026 GAAP diluted earnings rose 41% year-over-year to $2.01 per share.
- Total revenue climbed 39% to $492.97 million, while royalty revenue increased 44% to $341 million year-over-year.
- A Dutch patent court granted an injunction blocking Merck’s Keytruda Qlex launch in eight European markets for infringing a Halozyme patent.
- Full-year 2026 total revenue guidance increased to $1.86 billion–$1.93 billion, representing 33%–38% growth over 2025.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
CryptoQuant analyst says the altcoin market cap has shrunk by about $20 billion
![Fu Peng: Pay attention to the potential shift in copper from stockpiling to bottleneck logic [Fu Peng Commentary]](https://img.bgstatic.com/external-content/5bba8cd4c8254af78616bb3a2e614b63.jpg?w=420&h=236&f=webp)
Ripple's Dubai Event Presence Gets High-Profile Boost From Emirates Chairman
Signal of a rebound? Goldman Sachs US stock panic index reaches "extreme levels"
Goldman Sachs Volatility Panic Index surged to 9.57, approaching its maximum value, with the largest single-day increase ranking third in history, and the combined two-day volatility setting a new record. Historical data shows that after this index has exceeded the 9.5 threshold 15 times, the S&P 500 has seen an average three-month gain of 4.6% with a success rate of 80%. However, Goldman Sachs traders warn that forced liquidations have not yet fully cleared, and the market is still searching for a bottom, but opportunities on the other side are becoming increasingly difficult to ignore.
Crypto prices
More
